GlassScriptPhysician profile
Sofia Kennedy Prieto
NPI 1639526338
$2,401.71
in general payments reported to CMS, 2019-2025
19 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $113 · 2021: $230 · 2022: $118 · 2023: $754 · 2024: $525 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $644.00 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $321.71 | 2020-2024 | Xarelto |
| Abiomed | $198.60 | 2021-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $170.92 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.90 | 2020-2024 | Lifevest |
| Cvrx, INC. | $129.98 | 2023 | Barostim Neo System |
| Pfizer INC. | $110.92 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $103.89 | 2019 | |
| Boston Scientific Corporation | $101.38 | 2021-2025 | Cds - Mct/Cem Monitoring |
| Novo Nordisk INC | $90.09 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $86.33 | 2022-2023 | Verquvo |
| Atricure, INC. | $76.25 | 2023 | |
| Amgen INC. | $48.74 | 2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.18 | 2023-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $30.68 | 2023 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.60 | 2024-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $30.10 | 2023-2025 | Nexletol |
| Astellas Pharma US INC | $17.70 | 2019 | |
| Medtronic, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.